females, 75% Caucasians, 17% African-Americans, 8% other ethnicities. The mean age of patients was 46.6 years. For NCP, 17/36 (47%) of the patients switched qualitative NCP class (none, low, high) between baseline and followup, whereas for CAC only 3/35 (9%) switched qualitative class. Increasing years between assessments were associated with an increase in NCP (P = 0.038). The proportion of time on immunosuppressants was associated with a decrease in NCP (P = 0.06). Calcified coronary plaque levels remained relatively stable over a period of 2-8 years. Noncalcified coronary plaque levels were more variable. Use of immunosuppressive drugs appeared to be protective against noncalcified coronary plaque progression.
Introduction
The National Inpatient Sample in 1998 showed that there were 5000 hospitalizations, in the USA, among patients with systemic lupus erythematosus, due to coronary artery disease [1] , of which 1763 were due to acute myocardial infarction. In women <50 years of age, approximately 300 hospitalizations were due to myocardial infarction. It has been shown that the risk of cardiovascular events is increased 2.66-fold in the SLE population [2] .
Traditional stress tests used to diagnose coronary artery disease only detect flow-limiting stenosis and may miss early coronary atherosclerosis. Noninvasive imaging of coronary plaques resulted in major advances in our understanding of atherosclerosis and its pathogenesis. Coronary CT angiography is one such tool that can be integrated into the management of patients with known or suspected Abstract Premature coronary artery disease remains the major cause of late death in systemic lupus erythematosus (SLE). Coronary artery calcium (CAC) represents an advanced stage of atherosclerosis, whereas noncalcified coronary atherosclerotic plaque (NCP) typically is more prone to trigger acute coronary events. The aim of this study was to assess the stability of NCP over time and identify factors associated with changes in NCP in patients with SLE. CT coronary angiography and calcium scanning were performed at baseline and follow-up in thirty-six SLE patients. Duration between baseline and follow-up NCP assessment ranged from 2 to 8 years. CAC was quantified by the Agatston score and classified as none, low (1-99), moderate (100-299) or high calcium score (300 and above). NCP was quantified based on a previously validated score and classified as none, low (<0.5) or high (0.5+). SLE disease activity was quantified using the SELENA-SLE-DAI and physician global assessment indices. To assess the association between quantitative clinical variables and changes in NCP, adjusting for time, we used linear regression models. The group of 36 SLE patients were 75% 1 3 coronary atherosclerosis. It can assess the coronary lumen as well as volume and composition of coronary atherosclerotic plaque. Coronary CT angiography, unlike invasive coronary angiography, also gives detailed information about nonobstructive atherosclerosis within the coronary blood vessel wall. This is most helpful as we know that acute coronary syndromes are frequently caused by nonobstructive coronary plaques [3] .
A mature atherosclerotic plaque is composed of a lipid-/ macrophage-rich atheromatous material with an overlying fibrous cap. The cap may rupture and-in the right context-may trigger an acute coronary syndrome [4] . Plaque instability is related to the degree of ongoing inflammation [5] and plaque composition [6] . Coronary atherosclerotic plaques can be classified as calcified, noncalcified or mixed [7] [8] [9] . Often, noncalcified atherosclerotic plaques are more metabolically active than heavily calcified plaques and are associated with increased risk of acute coronary syndromes [10] . Noncalcified coronary plaque (NCP) and the total plaque burden of the coronary arteries, even of only one segment, are associated with an increased risk of cardiovascular events [11] . NCPs can even be found in individuals who have zero coronary calcium scores [11] . Although the coronary artery calcium score serves as a surrogate for total coronary atherosclerotic burden and correlates with risk of mortality [12] , it does not consider noncalcified plaque, which may be more relevant for risk assessment [4, [13] [14] [15] . Patients without any coronary atherosclerotic disease by CTA have exceedingly low risk of subsequent major adverse cardiovascular events and thus require no short-or intermediate-term follow-up for concerns of coronary artery disease [16] .
Increased prevalence of subclinical measures of coronary atherosclerosis including noncalcified plaque is seen in chronic diseases including HIV [17] and autoimmune diseases including rheumatoid arthritis [18] . In a study of 150 rheumatoid arthritis patients without prior symptoms or diagnosis of coronary artery disease and 150 controls, rheumatoid arthritis patients had a higher prevalence of NCP [18] . We have previously studied NCP cross-sectionally in SLE. We found that 54% of patients with SLE had NCP [19] . This is the first study of serial measurement of NCP in SLE. The aim of our study was to determine the frequency of progression and to evaluate the risk factors that lead to progression of NCP in patients with SLE, by serial CTA.
Methods
This is an observational longitudinal prospective study nested in the Johns Hopkins Lupus Cohort. Consecutive patients who consented to participate were assessed for NCP at baseline, and again 2-8 years later. Patients who were pregnant, allergic to contrast or had a serum creatinine level equal to or more than 1.2 mg/dL were excluded as previously described [19] . As part of the Hopkins Lupus Cohort, all patients were seen quarterly for the assessment of disease activity by physician's global assessment (PGA) on a visual analogue scale of zero to three and SELENA-SLEDAI [20, 21] . Laboratory tests including complete blood count, erythrocyte sedimentation rate (ESR), fasting lipid profile, homocysteine, serum creatinine, urinalysis, urine protein/creatinine ratio, complement C3 and C4, anti-dsDNA, anticardiolipin and lupus anticoagulant (by dRVVT) were done at each visit. Cardiovascular risk factors including weight, mean systolic blood pressure and history of smoking were assessed.
CT acquisition and image reconstruction
CT images were acquired using a 320 × 0.5 mm detector row CT system (Aquilion ONE, Toshiba Medical Systems, Otawara, Japan). Patient preparation included oral (75-150 mg) metoprolol. 50-70 mL of iodinated contrast (Iopamidol 370 mg iodine/mL) was injected intravenously at 4.0-6.0 mL/s for prospectively ECG-triggered acquisitions (typically 75% of the R-R interval). If coronary calcification was evident on angiographic images, a noncontrast CT acquisition was added to quantify calcium for the Agatston score. CT angiographic data were reconstructed to generate 0.5-mm-slice-thickness images with a 0.25-mm increment using both a standard (FC43) and a sharp (FC05) convolution kernel. Reconstructed images were transferred to a dedicated workstation for further analysis (Vitrea™ FX version 3.0 workstation, Vital Images, Minnetonka, MN, USA).
Coronary atherosclerotic plaque analysis
All images were interpreted by a physician, blinded to any clinical information, with extensive experience (level III certified) in the interpretation of coronary CT angiography. The left anterior descending coronary artery, left circumflex coronary artery and right coronary artery were divided into proximal, mid-and distal segments, respectively, according to standard segmentation guidelines [22] . The left main coronary artery was evaluated separately, resulting in ten segments evaluated in total. Each segment was assessed for the presence and severity of atherosclerotic plaques on a semiquantitative scale. Furthermore, plaque characteristics, including remodeling, were noted for each segment. These metrics were integrated for a total plaque severity score as previously described [23] . Briefly, the NCP score was the sum of plaque severity multiplied by plaque composition, divided by the number of vessels examined. Severity was calculated as 0 = absent, 1 = mild, 2 = moderate and 3 = severe for each coronary artery segment, according to the American Heart Association classification [24, 25] . Plaque composition was calculated as 0 = 0%, 1 = 1-25%, 2 = 26-50%, 3 = 51-75% and 4 = 76-100% in the noncalcified portion of coronary plaque for each coronary artery segment. Mild stenosis was defined as <25%, moderate 25-49% and severe ≥50%. Coronary artery side branches were not included in the analysis for practical and technical reasons, and also because the main branches have the bulk of disease. Noninterpretable coronary segments were excluded from our analysis. A segment was determined nonevaluable when either motion or poor contrast-to-noise ratio deemed detection of plaque impossible in the segment. Using this approach scores ranged from 0 to 1.7. For ease of description, we classified NCP as none, low (<0.5) or high (0.5+).
CAC was quantified by the Agatston score. CAC was classified as none, low if the Agatston score was 1-99, moderate if it was 100-299 or high if it was 300 and above [26] .
Statistical analysis
To quantify the clinical experience of patients between the two NCP assessments, we calculated the weighted mean value of the clinical variables measured during that period. The weights were calculated based on the interval between assessments so that the means calculated are interpretable as the average height of the curve based on a trapezoidal approach. This is equivalent to the method used to calculate the "adjusted mean SLEDAI" applied to other clinical variables [27] . We then estimated the association between these exposures and changes in the NCP score using linear regression, adjusting for the duration between NCP assessments.
Results
Thirty-six patients with a diagnosis of SLE were included in this study. The 36 SLE patients were 75% female. There were 75% Caucasians, 17% African-Americans and 8% other races/ethnicities. The age at the first assessment ranged from 22 to 75 with a mean of 46.6 years. Table 1 shows the ACR-11 criteria satisfied by our sample. Table 2 shows the percentage of patients using the different immunosuppressive drugs at the time of baseline and then at the time of follow-up scan.
A follow-up assessment of NCP was performed from 2 to 8 years after the baseline assessment. Thirty-six scans allowed repeat assessment for noncalcified plaque and thirty-five for coronary artery calcium. Of these followup assessments, 5 (14%) were performed in 2-3 years, 18 (50%) were performed in 3-4 years, and 13 (36%) were performed more than 4 years after baseline.
Twenty-four of 36 (75%) of the SLE patients had evidence of NCP at the first assessment. In contrast, only 12/35 (34%) had evidence of calcified plaque (a baseline measure of calcified plaque was missing for one patient). Those with noncalcified plaque were more likely to have calcified plaque than those without (11/23, 48% vs. 1/12, 8%, P = 0.027). Table 3 shows the results seen at follow-up in groups defined by baseline NCP. The pre-and post-scores were classified in the same category for 19 of 36 patients (53%). Progression occurred in 12/36 (33%) patients, and 5/36 (14%) patients showed plaque regression, implying that NCP levels were variable over a period of 2-8 years. Table 4 shows the baseline and follow-up CTA results for calcified coronary artery plaque. For calcified coronary plaque, the pre-and post-scores were in the same category for 32 of 35 patients (91%). Calcified coronary plaque progression occurred in 2/35 (5.71%) patients, and 1/35 (2.85%) patients showed regression of calcified plaque. This suggests that calcified coronary plaque levels remained relatively stable over a period of 2-8 years.
To identify predictors of NCP progression, we quantified clinical exposures experienced between the two NCP measures and assessed their association with changes in NCP score adjusting for time between assessments. Table 5 shows the results. There was a significant association between duration of time between assessments and increases in NCP (mean increase in NCP score per year 0.09, 95% confidence limits 0.02-0.17, P = 0.038). There was not a strong association between any of the clinical variables considered and changes in NCP. There was some evidence (P = 0.06) of an association between immunosuppressant use and less progression of NCP. 
Discussion
This study showed that calcified coronary plaque remained relatively stable over a period of 2-8 years, compared to noncalcified plaque, which was more variable. Neither traditional cardiovascular risk factors nor lupus-related disease activities were significantly associated with changes in NCP. There was some evidence that immunosuppressive drugs have a protective effect. In our previous Lupus Atherosclerosis Prevention Study (LAPS), two hundred SLE patients participated in a placebo-controlled trial of 40 mg atorvastatin [28] . It was shown that some SLE patients did have an increase in calcified coronary plaque burden over 2 years.
Progression of calcified coronary plaque was shown to be associated with age, current smoking status and total serum cholesterol, in the multivariate analyses. It was not associated with SLE disease activity, hypertension or anti-dsDNA [29] . Atorvastatin did not reduce calcified plaque in our LAPS trial [28] , nor in the pediatric trial [30] or in a murine model [31] .
In a cross-sectional study among patients in the Hopkins Lupus Cohort, one hundred and forty-seven patients underwent semiquantified assessment of NCP by 64-slice multi-detector computed tomography [23] . This included the baseline samples of the patients reported here. Patient age (P = 0.0001), current methotrexate use (P = 0.0005), history of anti-dsDNA positivity (P = 0.019) and obesity (assessed by body mass index, P = 0.058) were associated with the presence of NCP, in the multivariate model. Use of hydroxychloroquine and prednisone had no effect on the quantification of NCP [23] .
In contrast, a protective effect of methotrexate has been shown in rheumatoid arthritis patients. In a study of forty patients with rheumatoid arthritis, treatment of 1 year with methotrexate led to a decrease in carotid intima media thickness, shown by an overall decrease in atherosclerosis [32] . In a systematic literature review of 2420 abstracts, the use of methotrexate was associated with a decreased risk of cardiovascular events in patients diagnosed with rheumatoid arthritis [33] . In a study of 613 rheumatoid arthritis patients who were using disease-modifying antirheumatic drugs, especially methotrexate, a decreased risk of cardiovascular events was observed, when compared to rheumatoid arthritis patients who did not use methotrexate, hydroxychloroquine or sulfasalazine [34] .
A protective effect of mycophenolate mofetil on atherosclerosis was studied in gld.apoE −/−mice. These sevenweek-old mice were given a high-cholesterol Western diet for 12 weeks, with or without mycophenolate mofetil. Decreased atherosclerosis and decreased lupus phenotype were seen in the mice receiving mycophenolate mofetil, compared to controls [35] . Table 4 Number (%) with CAC at follow-up by baseline level "None" defined as an CAC score of 0, "low" defined as a CAC score >0 but <100, "moderate/high" was defined as a CAC score of 100 or more We do not have sufficient numbers of patients in this study to subdivide immunosuppressive use into methotrexate or mycophenolate mofetil. Immunosuppressive drug use in SLE is predominantly methotrexate and mycophenolate mofetil. The protective effect (that was nearly statistically significant, P = 0.06) of use of immunosuppressive drugs reflects mycophenolate mofetil use in the majority.
Our current study is the first to look at NCP over time in patients with SLE. Neither SLE disease activity, traditional cardiovascular risk factors nor lupus serologies predicted progression of NCP over time. There was no evidence that a history of smoking or current smoking status, mean systolic blood pressure, total serum cholesterol or BMI was associated with the progression of noncalcified coronary atherosclerotic plaque. Similarly, SLE-related risk factors including PGA, mean SLEDAI, lupus anticoagulant (by dRVVT), proportion of time with low C3 or C4 and positive anti-dsDNA were not associated with an increase in NCP score. Use of prednisone or hydroxychloroquine did not predict change in NCP.
This longitudinal study has enabled us to estimate rates of progression of NCP and to provide better evidence and greater resolution for identifying risk factors for plaque. However, given the small sample size, we cannot rule out the possibility that some subsets are associated with progression. Study of larger numbers of patients may allow identification of further predictors. Most importantly, we did find a near-significant protective effect of immunosuppressive use (mostly mycophenolate) on progression, consistent with animal models.
Key messages
• Noncalcified coronary plaque is more likely to undergo progression compared to calcified coronary plaque.
• Neither traditional cardiovascular risk factors nor SLE disease activity predict progression of NCP.
• Immunosuppressive drugs have a protective effect on the progression of NCP.
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